The objective of this study was to demonstrate the efficacy of iclaprim in a neutropenic rat lung infection model with methicillinresistant Staphylococcus aureus (MRSA) entrapped in alginate beads. An inoculum of 5.25 × 10 5 colony-forming units (CFU)/ mL of S. aureus strain AH1252 was administered intratracheally to rats with prepared alginate bacteria suspensions. Beginning 2 h post-infection, rats received: (1) iclaprim 80 mg/kg (n = 16); (2) iclaprim 60 mg/kg (n = 16), or (3) vancomycin 50 mg/kg (n = 24), for 3 days via subcutaneous (SC) injection every 12 h. Twelve hours after the last treatment, rats were euthanized and lungs collected for CFU determination. Iclaprim administered at 80 mg/kg or 60 mg/kg or vancomycin 50 mg/kg SC twice a day for 3 days resulted in a 6.05 log 10 CFU reduction (iclaprim 80 mg/kg compared with control, p < 0.0001), 5.11 log 10 CFU reduction (iclaprim 60 mg/kg compared with control, p < 0.0001), and 3.42 log 10 CFU reduction, respectively, from the controls (p < 0.0001). Iclaprim 80 mg/kg and 60 mg/kg resulted in 2.59 and 1.69 log 10 CFU reductions, respectively, from vancomycin-treated animals (80 mg/kg iclaprim vs. vancomycin, p = 0.0005; 60 mg/kg iclaprim vs. vancomycin, p = 0.07). Animals receiving iclaprim, vancomycin, and controls demonstrated 100%, 91.7%, and 48.3% survival, respectively. In this neutropenic rat S. aureus lung infection model, rats receiving iclaprim demonstrated a greater CFU reduction than the controls or those receiving vancomycin.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most common causes of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) [1, 2] . The annual incidence rate of healthcare-related MRSA pneumonia has increased from 11.3 cases per 100,000 patient days in 2008 to 15.5 cases per 100,000 patient days in 2012 [3] . MRSA causes invasive infections, like HAP and VAP, that are associated with organ dysfunction, poor outcomes with excess morbidity and mortality, and high costs to the healthcare system [4, 5] .
Iclaprim represents a diaminopyrimidine, which inhibits bacterial dihydrofolate reductase (DHFR) and is active against drug-resistant pathogens [6, 7] . Iclaprim exhibits potent in vitro activity against S. aureus, including MRSA [6] and linezolid-resistant and vancomycin-resistant S. aureus [8] that cause pneumonia. Iclaprim demonstrates rapid in vitro bactericidal activity in time-kill studies in human plasma [9] . Because of these findings, iclaprim is potentially well suited for treating patients with pneumonia caused by susceptible and multidrug-resistant pathogens, and the hypothesis of this study is that iclaprim would be effective in reducing colonyforming units (CFU) and prolonging survival among animals infected with MRSA compared to both vancomycin and controls.
The present study employed an experimental model of MRSA pulmonary infections as previously described [10] .
Notably, by encapsulating the bacteria within alginate, the infection model allowed for a lower inoculum to be utilized and a biofilm-type environment established within the lung.
Materials and methods

Collection of bacterial strains
Staphylococcus aureus AH1252 and AW6 were provided by IHMA and were gifts from Jose Entenza, Lausanne [11] . Strain AH1252 is a thymidine kinase-deficient mutant of the MRSA isolate AW6. Staphylococcus aureus ATCC 29213 was used as the Clinical and Laboratory Standards Institute (CLSI) quality control (QC) isolate for minimum inhibitory concentration (MIC) determinations.
Antimicrobial susceptibility testing
MICs were determined for iclaprim and vancomycin by broth microdilution according to CLSI criteria [12, 13] .
Preparation of bacteria
Test isolates were grown overnight on trypticase soy agar (TSA) from frozen stock cultures. After overnight incubation, colonies were resuspended in saline and adjusted to an optical density of 0.1 at 625 nm. The adjusted suspensions were further diluted in a 2% alginate buffer, which was added dropwise in a ratio of 1:5 into 50 mM CaCl 2 to form alginate beads. The alginate beads were stirred during the dropwise addition and then for an additional 30 min to ensure that the beads were fully formed. The bacterial preparation in alginate beads allowed for the establishment of a prolonged infection due to reduced efficiency of bacterial clearance with a low inoculum input. Serial dilutions of the inoculum preparations were performed to determine inoculum size (CFU per mL).
Preparation of compounds
Cyclophosphamide was prepared in sterile deionized water, and the mixture was vortexed and sonicated in a water bath sonicator until fully dissolved. Iclaprim was prepared by weighing out the appropriate amount and dissolving in 30% propylene glycol vehicle. The preparation was sonicated in a water bath sonicator until dissolved. Vancomycin was prepared in sterile deionized water and vortexed to dissolve.
Animal acquisition and acclimatization
All procedures in this protocol were in compliance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare. Upon receipt at NeoSome Life Sciences, Sprague Dawley male rats (Charles River Laboratories, Wilmington, MA) were examined by personnel to ensure acceptable health status. Veterinary care was provided by the veterinarians and staff employed by NeoSome Life Sciences.
Rats were acclimated for at least 5 days prior to testing. Rats were housed three per cage. The cage size met or exceeded the requirements set forth by the ILAR Guide for the Care and Use of Laboratory Animals. The animals were kept in a room maintained at 68-79°F (20-26°C), with humidity set at 30-70%. The room was illuminated with fluorescent lights timed to give a 12-h light, 12-h dark cycle. Rodent diet (Purina 5001) and water were available for all rats. The feed was analyzed by the supplier, detailing nutritional information and levels of specified contaminants.
Pretreatment, inoculation procedure, and treatment
Rats were pretreated with cyclophosphamide monohydrate to render them neutropenic. Based on literature review and previous experience with this model, rats were dosed intraperitoneally (IP) on day − 4 with 100 mg/kg. On day − 1 rats, received a second IP dose at 75 mg/kg [14, 15] . This regimen of neutropenia has been found to be effective in suppressing the immune system of the rat for this model.
Rats were infected with prepared alginate bacteria suspensions while under isoflurane anesthesia (4.5% isoflurane; 2.5 L/min O 2 ). Utilizing a sterile 20G, 3-inch stainless steel feeding needle, a 0.5-mL volume was delivered via intratracheal inoculation (IT). Holding the anesthetized rat in a vertical plane, the feeding needle was advanced into the trachea and the volume was instilled. The rat was returned to its cage and allowed to recover from the anesthesia.
Beginning at 2 h post-infection, rats were randomized to treatment with iclaprim, vancomycin, or 30% propylene glycol vehicle (controls). Test articles were prepared fresh for each day of dosing and formulated material was stored at 4°C, protected from light between the two daily doses. Animals were dosed by body weight in a volume of 5 mL/kg subcutaneously. These series of studies were designed to evaluate efficacy in a step-wise fashion. An initial dose of iclaprim 80 mg/kg per dose was selected based on a previous study in animal models of infection, including a model of bacteremia and abscess (unpublished data). Two different dosages of iclaprim (80 and 60 mg/kg) were used to show comparability with other iclaprim animal infection models and to establish which dose works best in this alginate bead model. Vancomycin was selected as a comparator based on activity observed in other rat models with difficult to treat infections [16, 17] and given its clinical use for staphylococcal infection. Non-treatment infection control animals received vehicle (30% propylene glycol).
Sample processing
No samples were collected before euthanasia. At 74 h postinfection, rats were euthanized by CO 2 inhalation. One group of rats was euthanized at 2 h post-infection to determine bioload at initiation of therapy. Rat lungs were aseptically removed, weighed, and homogenized to a uniform consistency using a Polytron PT 2100 with a 12-mm dispersing homogenizer (Bohemia, NY). The homogenized samples were serially diluted (10-fold dilutions) in sterile 0.9% saline and plated on TSA plates. The plates were incubated overnight at 37°C and CFU were enumerated by counting the plated colonies, adjusting for dilution factor and lung weight to obtain CFU/g of lung. The recovered bacteria were MRSA. While not conducted routinely, spot checking of bacteria recovered from the lung homogenates were also plated on oxacillin-containing media with the same results (same CFU count). This suggests that the recovered organisms were MRSA. Some minor contamination is expected with this model, though it is at low levels and most often a fungus or mold; both of these are easily identified and can be discounted when quantifying the CFU. This model has been previously validated and confirmed that the bacterial input and recovery are consistent. Additionally, the rats are maintained in a clean environment and are received from the vendor in good health (with health reports provided), which significantly limits the potential for contamination.
Statistical analyses
Group sizes of nine animals each were determined to be adequate through power analysis assuming 80% probability and a standard deviation of 0.5 log 10 CFU. These numbers allowed for the detection of 0.7 log 10 CFU between groups. The average, standard deviation, and standard error of the mean (SEM) CFU were calculated for each group of animals. One-way analysis of variance (ANOVA) with multiple comparison post-test (Bonferroni) was used to compare the means of CFU/g of lung between the experimental groups at two time points, 2 and 74 h post-infection. Specifically, comparisons were made of the 74 h post-infection CFU/g of lung and survival > 60 h between both iclaprim dosing regimens (80 and 60 mg/kg) compared to infection controls (vehicle alone), vancomycin compared to infection controls, and both iclaprim dosing regimens compared to vancomycin. A p-value ≤ 0.05 was considered to be significant.
Results
Against isolates AW6 and AH1252, the MIC values for iclaprim were 0.015 μg/mL for both and 0.5 and 0.25 μg/ mL for vancomycin, respectively. Table 1 and Fig. 1 show the CFU reduction and mortality by treatment. Rats infected with S. aureus AH1252 demonstrated an average bioload of 3.53 log 10 CFU/g of lung at the 2 h initiation of therapy. Besides MRSA, no other microorganisms were identified in the lungs of any animals. Untreated infected rat lungs demonstrated an average bioload of 8.70 log 10 CFU/g of lung at 74 h post-infection, a 5.17 log 10 CFU increase in bioburden over 72 h. Iclaprim administered at 80 mg/kg subcutaneously twice a day for 3 days resulted in a 6.05 log 10 CFU reduction from the 74 h infection controls (p < 0.0001). Additionally, a 0.88 log 10 CFU reduction was observed for iclaprim dosed at 80 mg/kg when compared with the bioload at initiation of therapy. This reduction suggests bacterial killing is occurring, which was not observed with vancomycin under these study conditions. Iclaprim administered 60 mg/kg subcutaneously twice per day demonstrated activity in the rat lung infection model with a 5.11 log 10 CFU reduction from the 74 h infection controls (p < 0.0001). In comparison, vancomycin administered at 50 mg/kg subcutaneously twice a day for 3 days demonstrated a 5.28 log 10 CFU/g of lung bioburden, a 3.42 log 10 CFU reduction from the 74 h infection controls (p < 0.0001). Iclaprim 80 mg/kg and 60 mg/kg resulted in 2.59 and 1.69 log 10 CFU reductions, respectively, from vancomycin-treated animals (80 mg/kg iclaprim vs. vancomycin, p = 0.0005; 60 mg/kg iclaprim vs. vancomycin, p = 0.07).
Control animals infected with S. aureus had 48.3% (14 of 29) survival. In contrast, animals receiving iclaprim had 100% survival (33 out of 33), while vancomycin-treated animals had 91.7% (22 out of 24) survival (both iclaprim-and vancomycin-treated animals showed increased survival compared to control animals, chi-square test, p < 0.01).
Discussion
This report demonstrates that iclaprim produces significant and sustained efficacy in the current pulmonary model of lung infection due to MRSA, compared with vancomycin. The data support the potential use of iclaprim in the treatment of staphylococcal pulmonary infections. The combination of the alginate encapsulated bacteria and ensuing biofilm formation established a bacterial growth environment that was difficult to treat and eradicate, providing a useful model to test the ability of antibiotics to treat challenging pulmonary bacterial infections. Patients with cystic fibrosis can have S. aureus pulmonary infections. Therefore, it is important that antibiotics aiming to treat such infections be able to distribute and concentrate in the lung compartments.
A Phase 1 study investigated the tissue distribution of a single intravenous (IV) dose of iclaprim in relevant lung compartments [18] . Iclaprim concentrations found in epithelial ling fluid (ELF) and alveolar macrophages (AM) were up to 20-and 40-fold higher, respectively, than in plasma. In addition, iclaprim concentrations in plasma, ELF, and AM after a single IV dose of 1.6 mg/kg exceeded iclaprim MICs for penicillin-susceptible S. pneumoniae (MIC 90 0.06 mg/L) and MRSA (MIC 90 0.12 mg/L) for up to 7 h; the mean iclaprim concentrations in ELF exceeded the iclaprim MICs observed for S. pneumoniae with intermediate penicillin resistance (MIC 90 2 mg/L) and full resistance (MIC 90 4 mg/L) for up to 7 and 4 h, respectively, after a single dose.
Staphylococcus aureus AH1252 strain, which is deficient in thymidine kinase, was used in this study because it has been reported that the uptake of exogenous thymidine and its conversion into thymidylate by thymidine kinase in certain bacteria, including S. aureus, antagonize with the antimicrobial activity of the DHFR inhibitor trimethoprim in vitro [19] . It is also known that the serum of rodents contains large concentrations of thymidine compared to human serum, i.e., ≥ 1 and ≤ 0.01 μg/mL, respectively [19] . This is the most plausible reason to explain why testing trimethoprim or trimethoprimsulfamethoxazole (TMP-SMX) can sometimes be ineffective in staphylococcal infection models in rodents [12, 17] . A previous study by Entenza et al. [11] described the use of S. aureus thymidine kinase-deficient mutants (unable to utilize exogenous thymidine) in an in vitro fibrin clot model employing iclaprim in the presence of rat and human clots. The utility of the thymidine kinase mutants was evident, as thymidine no longer antagonized the action of iclaprim in the rat. Thus, iclaprim demonstrated high efficacy in rat (high thymidine) containing clots generated in the presence of these thymidine kinase-deficient S. aureus strains, but not, as expected, with the thymidine kinase-producing wild-type strains [11] .
There are limitations to this study. First, only two doses and two timepoints with a single inoculum challenge were used in this study. No pharmacokinetics (i.e., no blood or lung levels of iclaprim or vancomycin) were performed because the two doses were based on previous studies of iclaprim in animal infection models and mimicking exposures in patients (unpublished data). Second, the starting inoculum in rodents was low compared to other models because, by encapsulating bacteria within alginate, the infection model allowed for a lower inoculum to be utilized and a biofilm-type environment established within the lung. Although this may lower the therapeutic hurdle, all groups, control and iclaprim-and vancomycin-treated rats, received the same starting inoculum. Furthermore, this starting inoculum is consistent with other published alginate bead pneumonia models [10] . Third, no microbiological samples or counts were collected or measured before euthanasia of the animals; therefore, the initial challenge might not be the same in the lungs. This current pulmonary model of lung infection due to MRSA is consistent with the results from a Phase 2 study showing activity of iclaprim in patients with nosocomial pneumonia. In the Phase 2 study, the clinical cure rates of two iclaprim dosages were compared with that of vancomycin in the treatment of patients with nosocomial pneumonia suspected or confirmed to be caused by Gram-positive pathogens; this study showed iclaprim and vancomycin to have comparable clinical cure rates and safety profiles in these patients [20] . The cure rates in the intent-to-treat population were 73.9% (17 of 23), 62.5% (15 of 24), and 52.2% (12 of 23) at the post-treatment test of cure visit in the iclaprim 0.8 mg/kg IV q12h, iclaprim 1.2 mg/kg IV q8h, and vancomycin 1 g IV q12h groups, respectively (iclaprim q12h vs. vancomycin p = 0.13; and iclaprim q8h vs. vancomycin p = 0.47). The death rates within 28 days of the start of treatment were 8.7% (2 of 23), 12.5% (3 of 24), and 21.7% (5 of 23) for the iclaprim q12h, iclaprim q8h, and vancomycin groups, respectively (no statistically significant differences).
Collectively, the current in vivo study and previous Phase 1 and 2 clinical studies support the use of iclaprim development as a potential treatment for S. aureus pneumonia, including possibly among patients with biofilm-mediated infection, as seen, for example, in cystic fibrosis.
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